As regulatory, pricing and policy dynamics whipsaw in the United States, healthcare and life sciences firms are facing enormous pressures to keep profits rising, with those challenges now “becoming more acute by the quarter,” according to an inaugural industry distress survey from consulting firm AlixPartners. In the industry poll, which queried 200 U.S.-based healthcare and life sciences operators, investors and advisors, regulatory and policy uncertainty was rated by respondents as the leading challenge for companies of all stripes. While many of those companies, investors and advisors believe it’s possible to grow beyond present hurdles, that mindset “could prove costly,” per the report.
Read the full article: Amid Policy and Pricing Headwinds, US Healthcare and Life Sci Faces ‘Vast Field of Opportunity’: Survey //
Source: https://www.fiercepharma.com/pharma/amid-policy-and-pricing-headwinds-us-healthcare-and-life-sci-faces-vast-field-opportunity